← All trials
NCT07227246
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2025
- Primary completion
- Jan 31, 2029
- Completion date
- Jun 30, 2029
- First posted
- Nov 12, 2025
- Last posted
- Nov 12, 2025
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CincinnatiLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of CincinnatiSponsor investigator
- Novo NordiskCollaborator
- Japan Agency for Medical Research and DevelopmentCollaborator
- University of CincinnatiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.